Kimmo Porkka

University of Alicante — Spain

Medicine · Health Sciences

69h-index23.9kcitations641works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(199), Chronic Lymphocytic Leukemia Research(176), Acute Myeloid Leukemia Research(167), Acute Lymphoblastic Leukemia research(58), Eosinophilic Disorders and Syndromes(52)

Publications641 total

Supplementary Tables from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
2025Open Access
Supplementary Figures from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
2025Open Access
Supplementary Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
2025Open Access
Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland
Clinical Lymphoma Myeloma & Leukemia·2025Open Access
TIM3 blockade with hypomethylating therapy restores NK and cytotoxic CD4+ T cell activity in patients with AML or MDS
2025Open Access
Enhancing Severe Neutropenia Prediction: <scp>PKPD</scp> ‐Informed Labeling for Machine Learning Models Trained on Real‐World Data
Clinical Pharmacology & Therapeutics·2025· 1 citedOpen Access
Randomized comparison of ponatinib versus imatinib in combination with chemotherapy in patients 55 years of age and older with newly diagnosed ph+ ALL: Molecular response and initial outcome analysis of the EWALL PH03 Study
Blood·2025
Anti-TIM3 with hypomethylating agent revives NK and cytotoxic CD4+ T cell activity in patients with AML or MDS
Blood·2025
146eP FALCON-bladder, from real-world evidence to impact: Piloting a global assessment of oncology guideline adoption, relevance and generalizability
ESMO Real World Data and Digital Oncology·2025Open Access
Sensitivity to ATR–CHK1 pathway inhibition in AML/MDS is enhanced by <i>SRSF2</i> mutations and reduced by RUNX1 loss
2025Open Access
P1.17.67 A Large-Scale Network Study on Impact of Immune Checkpoint Therapy in Metastatic Non-Small Cell Lung Cancer: The iCan mNSCLC Study-A-Thon
Journal of Thoracic Oncology·2025
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial
Universität Zürich, ZORA·2025Open Access
Changes in use and utilisation patterns of drugs with reported shortages between 2010 and 2024 in Europe and North America: a network cohort study
The Lancet Public Health·2025· 1 citedOpen Access
Predictors of response and rational combinations for the novel <scp>MCL</scp> ‐1 inhibitor <scp>MIK665</scp> in acute myeloid leukemia
Molecular Oncology·2025· 1 citedOpen Access
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial
Leukemia·2025Open Access
1867P FALCON-Lung: Evolving global ICI treatment patterns and outcomes in the era of personalized mNSCLC treatment
Annals of Oncology·2025· 2 cited
2318P FALCON: A novel high-quality cancer network for RWE
Annals of Oncology·2025
2718P Characterising treatment and overall survival of chondrosarcoma patients across Europe using real-world data (RWD): Data analysis and real-world interrogation network (DARWIN EU) cohort study
Annals of Oncology·2025
Supplementary Figure S15 from A Machine Learning–Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia
2025Open Access
Supplementary Figure S1 from A Machine Learning–Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia
2025Open Access
page 1 of 33Next →

Frequent Co-authors

Satu Mustjoki(18), Olli Kallioniemi(10), Caroline A. Heckman(9), Mika Kontro(9), Samuli Eldfors(8), Krister Wennerberg(8), Heikki Kuusanmäki(7), Jorma Viikari(6), Pekka Ellonen(5), Sonja Lagström(5), Muntasir Mamun Majumder(5), Alun Parsons(5), Gianantonio Rosti(5), Michele Baccarani(5), Henrik Hjorth‐Hansen(5), Tea Pemovska(5), Bhagwan Yadav(5), Bjørn Tore Gjertsen(5), Tero Aittokallio(5), Andrew H. Wei(4)